News Focus
News Focus
icon url

novicetrader

05/23/19 8:39 AM

#46883 RE: James salmon #46882

With the bad news out of the way,now time for the good news to trickle in. Today's news:
UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer

https://finance.yahoo.com/news/ucsf-doses-first-patient-triple-123000054.html
icon url

chickpea598

05/23/19 9:04 AM

#46885 RE: James salmon #46882

Oncosec is now trading way below book value with around $30 million in cash.
icon url

itk331

05/23/19 9:56 AM

#46887 RE: James salmon #46882

James, appreciate the positive outlooks, however as most here are aware, we heard/read similar positivity after public offerings of Advaxis to raise 20 million or so.. more than once.. and we all know how that one ended.. (countless times people said this is the bottom and the only way was up, which was all a big lie) So, what’s the guarantee (or at least a clue?) with OncoSec, having Dan on the helm, to not be fooled again and get sucked in to further traps in the land of shady looking baby bio arena?